title: Effect of CCK on food intake in man: physiological or pharmacological effect?
abstract: The present study was designed to determine in humans the dose of CCK which suppresses food intake. 18 male subjects received in randomized order either i.v. saline or Thr28 Nle31 CCK 25-33 (CCK-9) at 100 or 500 pmol/kgh, respectively. In addition, 7 subjects received CCK together with the opiate receptor antagonist naloxone to examine if activation of endogenous opioids might interfere with the potential satiating effect of CCK. Food intake during saline was 32 +/- 2 sandwiches (mean +/- SEM), during CCK-9 100 pmol/kgh 28 +/- 2 (n.s.) and only 12 +/- 3 during CCK-9 500 pmol/kgh (p less than 0.01). The respective water intake was 730 +/- 70 ml, 590 +/- 60 ml (n.s.) and 320 +/- 50 ml (p less than 0.01). Naloxone further reduced food and water intake during high but not low dose CCK or saline. During saline postprandial insulin levels rose by 49 +/- 6 microU/ml within 45 min which was attenuated during low dose (23 +/- 6 microU/ml; p less than 0.01) and high dose CCK-9 (1 +/- 1 microU/ml; p less than 0.001). Plasma glucagon did not change in control or CCK experiments. The postprandial rise of pancreatic polypeptide was attenuated during high dose CCK. Naloxone had no effect on the hormonal response except for a prolonged reduction of insulin and glucose levels following high dose CCK + naloxone. Plasma CCK levels rose by 5.4 pmol/l in controls but by 55 and 255 pmol/l during the low and high dose CCK infusion, respectively. These data demonstrate that suppression of food intake in man by i.v. CCK is a pharmacological rather than a physiological effect.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine II, Technical University of Munich, Germany.
authors.forename: R R
authors.initials: RR
authors.lastname: Schick
authors.forename: V
authors.initials: V
authors.lastname: Schusdziarra
authors.forename: J
authors.initials: J
authors.lastname: Mössner
authors.forename: J
authors.initials: J
authors.lastname: Neuberger
authors.forename: B
authors.initials: B
authors.lastname: Schröder
authors.forename: R
authors.initials: R
authors.lastname: Segmüller
authors.forename: V
authors.initials: V
authors.lastname: Maier
authors.forename: M
authors.initials: M
authors.lastname: Classen
mesh_terms: D000328:Adult; D000681:Amylases / Q000097:blood; D000818:Animals; D001066:Appetite / Q000187:drug effects / Q000502:physiology*; D002766:Cholecystokinin / Q000494:pharmacology* / Q000502:physiology*; D046508:Culture Techniques; D004305:Dose-Response Relationship, Drug; D004326:Drinking / Q000187:drug effects / Q000502:physiology; D004435:Eating / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D010179:Pancreas / Q000187:drug effects; D010446:Peptide Fragments / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012528:Satiety Response / Q000187:drug effects / Q000502:physiology*; D012844:Sincalide / Q000494:pharmacology
chemical_list: D010446:Peptide Fragments; C053399:cholecystokinin 9; D009270:Naloxone; D002766:Cholecystokinin; D000681:Amylases; D012844:Sincalide